Intelsat Continues Investment in Global 5G Software-Defined Network with Acquisition of Two Software-Defined Satellites from Thales Alenia Space
12.1.2022 13:00:00 EET | Business Wire | Press release
Intelsat, operator of the world’s largest integrated satellite and terrestrial network, and Thales Alenia Space, Joint Venture between Thales (67%) and Leonardo (33%) have signed an agreement to build two software-defined satellites designed to advance Intelsat’s global fabric of software-defined GEO connectivity as part of its 5G software-defined network.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220112005271/en/
The artist’s view represents the two Intelsat software-defined satellites, IS-41 and IS-44, with the corresponding antennas configuration. (courtesy: Thales Alenia Space).
The addition of the Thales Alenia Space software-defined satellites represents an essential advancement in Intelsat’s 5G software-defined network designed to enable greater agility, flexibility and orchestration across edge, satellite and core. Named Intelsat 41 (IS-41) and Intelsat 44 (IS-44), the two next-generation software-defined satellites are scheduled to be in service in 2025. They will join two Airbus constructed software-defined satellites, Intelsat 42 (IS-42) and Intelsat 43 (IS-43), announced January 8, 2021.
Intelsat 41 and Intelsat 44 will be based on the Thales Alenia Space’s innovative Space Inspire product line allowing seamless telecommunications mission and services reconfiguration, instant in-orbit adjustment to broadband connectivity demand, and superior video broadcasting performance while maximizing the effective use of the satellite resources.
“Intelsat’s standards-based, open-architecture network design facilitates the incorporation of the best technology at any given time, further bolstering network resiliency,” said Stephen Spengler, CEO of Intelsat. “With the addition of Intelsat 41 and Intelsat 44, in partnership with Thales Alenia Space, Intelsat will blanket the earth with software-defined satellites, progressing the world’s first global 5G software-defined network, designed to unify the global telecoms ecosystem.”
The contract enables the continued advancement of Intelsat’s planned global software-defined satellite-based network, adding high-speed dynamically-allocated connectivity across Africa, Europe, the Middle East and Asia for commercial and government mobility services and cellular backhaul.
“Our relationship with Intelsat has been so meaningful knowing that our attractive Space Inspire software-defined solution will contribute to the realization of Intelsat’s global 5G software-defined unified network,” said Hervé Derrey, CEO of Thales Alenia Space. “We are proud that our advanced satellite technology will play a significant role in Intelsat’s vision to reimagine the global telecoms ecosystem.”
About Intelsat
As the foundational architects of satellite technology, Intelsat operates the world’s most trusted satellite telecom network. We apply our unparalleled expertise and global scale to connect people, businesses, governments and communities, no matter how difficult the challenge. Intelsat is building the future of global communications with the world’s first hybrid, multi-orbit, software-defined 5G network designed for simple, seamless, and secure coverage precisely when and where our customers most need it. Follow the leader in global connectivity and “Imagine Here,” with us, at Intelsat.com .
About Thales Alenia Space
Drawing on over 40 years of experience and a unique combination of skills, expertise and cultures, Thales Alenia Space delivers cost-effective solutions for telecommunications, navigation, Earth observation, environmental management, exploration, science and orbital infrastructures. Governments and private industry alike count on Thales Alenia Space to design satellite-based systems that provide anytime, anywhere connections and positioning, monitor our planet, enhance management of its resources, and explore our Solar System and beyond. Thales Alenia Space sees space as a new horizon, helping to build a better, more sustainable life on Earth. A joint venture between Thales (67%) and Leonardo (33%), Thales Alenia Space also teams up with Telespazio to form the parent companies’ Space Alliance, which offers a complete range of services.
Thales Alenia Space has around 7,700 employees in 10 countries with 17 sites in Europe and a plant in the U.S. www.thalesaleniaspace.com .
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220112005271/en/
Contact information
Melissa Longo, Intelsat, +1 (240) 308-1881, melissa.longo@intelsat.com
Thales Alenia Space contact(s)
Sandrine Bielecki, +33 (0)4 92 92 70 94, sandrine.bielecki@thalesaleniaspace.com
Catherine des Arcis, +33 (0)6 78 64 63 97, catherine.des-arcis@thalesaleniaspace.com
Marija Kovac, +39 (0)6 415 129 91, marija.kovac-somministrato@thalesaleniaspace.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom